Home
Amgen AMGN paid Forbes-Tate $80K for lobbying in Q1 2026 · Medicare, Medical and 2 more issues
Trade details
- Type
- Lobbying report
- Amount
- $80,000
- Quarter
- Q1 2026
- Stock
- Amgen AMGN
- Client
- Amgen
- Reported
- 26/04/17
Up 0.0% from last quarter
What else happened in Amgen around then
Filed or reported within 30 days of the trade day · 03/01~04/30Amgen's other lobbying reports
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
Under $5,000
Under $5,000
Reported 07/28
for Q2
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
Under $5,000
Under $5,000
Reported 07/21
for Q2
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
$50K
$50K
Reported 07/20
for Q2
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
$80K
$80K
Reported 07/20
for Q2
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
$60K
$60K
Reported 07/20
for Q2